In ROS1-mutated NSCLC, with progression occurring after treatment with crizotinib or ceritinib, including cases with CNS progression, entrectinib or repotrectinib are potential alternatives311 and lorlatinib is also a viable option.49 In EGFR-mutated tumors that have acquired resistance to EGFR TKIs, HER3 expression is typically upregulated. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.